X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs STERLING BIOTECH - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA STERLING BIOTECH AUROBINDO PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 14.7 -0.6 - View Chart
P/BV x 3.8 0.0 16,296.1% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 AUROBINDO PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
STERLING BIOTECH
Dec-13
AUROBINDO PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs89511 8,523.8%   
Low Rs6223 18,294.1%   
Sales per share (Unadj.) Rs254.626.8 949.7%  
Earnings per share (Unadj.) Rs39.3-15.0 -262.6%  
Cash flow per share (Unadj.) Rs46.6-5.5 -852.6%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs160.054.9 291.5%  
Shares outstanding (eoy) m585.88267.87 218.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.00.3 1,149.2%   
Avg P/E ratio x19.3-0.5 -4,155.9%  
P/CF ratio (eoy) x16.3-1.3 -1,280.0%  
Price / Book Value ratio x4.70.1 3,744.4%  
Dividend payout %6.40-   
Avg Mkt Cap Rs m444,3901,862 23,870.1%   
No. of employees `00014.01.4 1,032.6%   
Total wages/salary Rs m17,678547 3,232.9%   
Avg. sales/employee Rs Th10,667.85,303.3 201.2%   
Avg. wages/employee Rs Th1,264.3403.8 313.1%   
Avg. net profit/employee Rs Th1,645.8-2,959.0 -55.6%   
INCOME DATA
Net Sales Rs m149,1577,181 2,077.2%  
Other income Rs m1,15943 2,720.4%   
Total revenues Rs m150,3167,223 2,081.0%   
Gross profit Rs m34,343947 3,626.9%  
Depreciation Rs m4,2762,543 168.1%   
Interest Rs m6674,377 15.2%   
Profit before tax Rs m30,558-5,931 -515.2%   
Minority Interest Rs m500-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,597-1,924 -394.8%   
Profit after tax Rs m23,012-4,007 -574.4%  
Gross profit margin %23.013.2 174.6%  
Effective tax rate %24.932.4 76.6%   
Net profit margin %15.4-55.8 -27.7%  
BALANCE SHEET DATA
Current assets Rs m92,06214,335 642.2%   
Current liabilities Rs m66,22349,809 133.0%   
Net working cap to sales %17.3-494.0 -3.5%  
Current ratio x1.40.3 483.0%  
Inventory Days Days106403 26.3%  
Debtors Days Days68171 39.7%  
Net fixed assets Rs m62,91955,432 113.5%   
Share capital Rs m586268 218.7%   
"Free" reserves Rs m93,13313,935 668.3%   
Net worth Rs m93,71914,701 637.5%   
Long term debt Rs m1,8149,478 19.1%   
Total assets Rs m162,49473,988 219.6%  
Interest coverage x46.8-0.4 -13,184.7%   
Debt to equity ratio x00.6 3.0%  
Sales to assets ratio x0.90.1 945.8%   
Return on assets %14.60.5 2,909.3%  
Return on equity %24.6-27.3 -90.1%  
Return on capital %32.7-6.4 -509.5%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m75,8381,860 4,077.7%   
Fx outflow Rs m30,22425 121,431.5%   
Net fx Rs m45,6131,835 2,485.9%   
CASH FLOW
From Operations Rs m32,7861,719 1,907.6%  
From Investments Rs m-17,870-3,148 567.6%  
From Financial Activity Rs m-19,1531,426 -1,343.1%  
Net Cashflow Rs m-4,239-3 124,667.6%  

Share Holding

Indian Promoters % 54.1 33.9 159.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 0.0 -  
FIIs % 27.7 9.9 279.8%  
ADR/GDR % 0.0 16.9 -  
Free float % 10.2 39.3 26.0%  
Shareholders   69,601 21,482 324.0%  
Pledged promoter(s) holding % 8.6 55.9 15.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   SUN PHARMA  MERCK LTD  GSK PHARMA  J.B.CHEMICALS  DR. REDDYS LAB  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 0.4%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 0.4% YoY). Sales on the other hand came in at Rs 40 bn (up 11.2% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jun 21, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS